Proton Pump Inhibitor (PPI) sebagai Farmakoterapi GERD pada Lansia
DOI:
https://doi.org/10.55175/cdk.v50i7.635Kata Kunci:
Gastroesophageal reflux disease, lansia, proton pump inhibitorAbstrak
Gastroesophageal reflux disease (GERD) merupakan salah satu penyakit gastrointestinal (GI) paling umum pada lanjut usia (lansia). Gejala GERD pada lansia umumnya atipikal dan tidak terlalu parah, namun lebih berisiko terjadi kelainan mukosa dan komplikasi. Proton pump inhibitor (PPI) masih menjadi sarana farmakoterapi terapi lini pertama pasien GERD lansia. Namun, penggunaan PPI pada lansia dikaitkan dengan beberapa efek samping. Hingga saat ini, belum ada konsensus mengenai durasi optimal penggunaan PPI pada lansia.
Gastroesophageal reflux disease (GERD) is one of the most common gastrointestinal (GI) diseases in the elderly. GERD symptoms in the elderly are generally atypical and less severe, but with a higher risk of mucosal abnormalities and complications. Proton pump inhibitor (PPI) therapy is still the first line pharmacotherapy for elderly GERD patients. However, PPI use in elderly are associated with several side effects. To date, there is no consensus yet on the optimal duration of PPI use in the elderly.
Unduhan
Referensi
Piper MS, Hall KE. Gastroenterology. Geriatrics for specialists. 2021:279-80. https://doi.org/10.1007/978-3-030-76271-1_21
Kurin M, Fass R. Management of gastroesophageal reflux disease in the elderly patient. Drugs & Aging. 2019;36(12):1073–81. https://doi.org/10.1007/s40266-019-00708-2
Locke GR, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ. Prevalence and clinical spectrum of gastroesophageal reflux: A population-based study in Olmsted County, Minnesota. Gastroenterology. 1997;112(5):1448–56. DOI:10.1016/s0016-5085(97)70025-8
Notariza KR, Nurcholis, Yusaryahya H, Karimah NS, Mansur AY, Adhiguna G, et al. Gastroesophageal reflux disease among elderly type 2 diabetes mellitus in a rural area of Central Sulawesi: A cross-sectional study. Acta Medica Indon. 2021;53(1):42-51.
Ahmed A, Clarke JO. Proton pump inhibitors (PPI). StatPearls [Internet]. 2021 [cited 2023 Feb 13]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557385/
Pilotto A, Leandro G, Franceschi M. Short- and long-term therapy for reflux oesophagitis in the elderly: A multi-centre, placebo-controlled study with pantoprazole. Alimentary Pharmacol Therapeutics. 2003;17(11):1399–406. DOI:10.1046/j.1365-2036.2003.01593.x
James OFW, Parry-billings KS. Comparison of omeprazole and histamine H2-receptor antagonists in the treatment of elderly and young patients with reflux oesophagitis. Age Ageing. 1994;23(2):121–6. DOI: 10.1093/ageing/23.2.121
Hasselgren G, Hassan-Alin M, Andersson T, Claar-Nilsson C, Röhss K. Pharmacokinetic study of esomeprazole in the elderly. Clin Pharmacokinetics. 2001;40(2):145–50. DOI: 10.2165/00003088-200140020-00006
Lin SF, Lin PC, Chang CC, Chang WL, Chu FY. Investigation of the interaction between proton pump inhibitors and clopidogrel using VerifyNow P2Y12 assay. Medicine. 2020;99(50):e23695. DOI: 10.1097/MD.0000000000023695
Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: Expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017;152(4):706–15. DOI:10.1053/j.gastro.2017.01.031
Wu CY, Xiong LY, Ouk M, Rabin JS, Herrmann N, Lanctôt KL, et al. Gastric acid suppressants and cognitive decline in people with or without cognitive impairment. Alzheimer's Dementia: Translational Res Clin Interventions. 2022;8(1). DOI: 10.1002/trc2.12243
Chen LY, Lin HJ, Wu WT, Chen YC, Chen CL, Kao J, et al. Clinical use of acid suppressants and risk of dementia in the elderly: A pharmaco-epidemiological cohort study. Internat J Environment Res Publ Health. 2020;17(21):8271. DOI:10.3390/ijerph17218271
Thong BK, Ima-Nirwana S, Chin K-Y. Proton Pump Inhibitors and Fracture Risk: A review of current evidence and mechanisms involved. Internat Environment Res Publ Health. 2019;16(9):1571. DOI:10.3390/ijerph16091571
Maes ML, Fixen DR, Linnebur SA. Adverse effects of proton-pump inhibitor use in older adults: A review of the evidence. Therapeutic Advances in Drug Safety. 2017;8(9):273–97. DOI: https://doi.org/10.1177/2042098617715381
Mafi JN, May FP, Kahn KL, Chong M, Corona E, Yang L, et al. Low‐value proton pump inhibitor prescriptions among older adults at a large academic health system. J Am Geriatr Soc. 2019;67(12):2600–4. DOI: 10.1111/jgs.16117
Boustani M, Hall KS, Lane KA, Aljadhey H, Gao S, Unverzagt F, et al. The association between cognition and histamine-2 receptor antagonists in African Americans. Journal of the American Geriatrics Society. 2007;55(8):1248–53. DOI: https://doi.org/10.1111/j.1532-5415.2007.01270.x
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2023 Cermin Dunia Kedokteran
Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.
